ENLIVEN THERAPEUTICS, INC. Nrrtv Max Aggt Offering Pric
ENLIVEN THERAPEUTICS, INC. (ELVN) had Nrrtv Max Aggt Offering Pric of $525.00 million as of 2026-06-12, per its 424B5 filed 2026-06-12.
Financial Statements › Notes
ffd:NrrtvMaxAggtOfferingPric · last filed 2026-06-12
- 2026-06-12: Nrrtv Max Aggt Offering Pric $525.00M.
| Period end | Nrrtv Max Aggt Offering Pric |
|---|---|
| 2026-06-12 | $525.00M 424B5 · filed 2026-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |